Blog

Post 1:  What Boardroom Readiness Really Look Like:  Lessons from the C-Suite Over the course of a 30+ year career straddling the business and legal sides of the life sciences industry, I’ve worked alongside public company boards as both an executive team member and as outside counsel. I’ve also served on private company and not-for-profit…

Insights on Modern Corporate Governance from the Front Lines of Law, Business, and Life SciencesBy Al Parker Over the course of a 30-year career at the intersection of law, business, and the life sciences industry, I’ve worn many hats—CEO, COO, Chief Legal Officer, board advisor, outside counsel, and independent director. I’ve worked alongside high-performing boards…

Small and mid-cap life sciences companies often operate with a mix of urgency and ambition. Whether they’re advancing through clinical milestones, preparing for commercialization, or contemplating a public offering, these companies need to scale fast —but scaling smart is the real challenge. In this stage of growth, governance and operational infrastructure can either serve as…

The Audit Committee’s Expanding Role: Risk, Cybersecurity, and Compliance in Life Sciences Governance In today’s life sciences sector—where regulatory scrutiny is high, innovation moves fast, and data is everything—the role of the audit committee is undergoing a fundamental shift. Once focused almost exclusively on financial reporting and internal controls, audit committees are now squarely in…

Commercial partnerships are crucial for biotech and pharmaceutical companies looking to accelerate innovation, reduce costs, and bring new therapies to market. Whether it’s a licensing deal, co-development agreement, or joint venture, these collaborations provide a way for companies to leverage each other’s strengths. However, structuring these partnerships requires careful legal and strategic planning to protect…